Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS

British Journal of Haematology

Volumn 167, Issue 1, 2014, Pages 62-68

  Zeidan, Amer M ^a   Lee, Ju Whei ^b   Prebet, Thomas ^c   Greenberg, Peter ^d   Sun, Zhuoxin ^b   Juckett, Mark ^e   Smith, Mitchell R ^f   Paietta, Elisabeth ^g   Gabrilove, Janice ^h   Erba, Harry P ⁱ   Katterling, Rhett P ^j   Tallman, Martin S ^k   Gore, Steven D ^a  

^a YALE UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c AIX MARSEILLE UNIVERSITY   (France)

^d STANFORD CANCER INSTITUTE   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f TAUSSIG CANCER INSTITUTE   (United States)

^g MONTEFIORE MEDICAL CENTER   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j MAYO CLINIC   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

Azacitidine; French prognostic scoring system; Myelodysplastic syndromes; Prognostic models; Revised international prognostic scoring system

Indexed keywords

AZACITIDINE; ENTINOSTAT; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; DRUG RESPONSE; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; OLIGOBLASTIC ACUTE MYELOID LEUKEMIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; THROMBOCYTE COUNT; TREATMENT OUTCOME; VERY ELDERLY; BLOOD; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PLATELET COUNT; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84911008768     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13008     Document Type: Article

References (29)

1. Faltas, B., Zeidan, A. & Gergis, U. (2013) Myelodysplastic syndromes: toward a risk-adapted treatment approach. Expert Review of Hematology, 6, 611-624.
2. Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., Gore, S.D., Seymour, J.F., Bennett, J.M., Byrd, J., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C., Silverman, L.R. & International Vidaza High-Risk MDS Survival Study Group (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. The Lancet Oncology, 10, 223-232.
3. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088.
4. Greenberg, P.L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Sole, F., Bennett, J.M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, A., Malcovati, L., Cazzola, M., Cermak, J., Fonatsch, C., Le Beau, M.M., Slovak, M.L., Krieger, O., Luebbert, M., Maciejewski, J., Magalhaes, S.M., Miyazaki, Y., Pfeilstocker, M., Sekeres, M., Sperr, W.R., Stauder, R., Tauro, S., Valent, P., Vallespi, T., van de Loosdrecht, A.A., Germing, U. & Haase, D. (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood, 120, 2454-2465.
5. van der Helm, L.H., Alhan, C., Wijermans, P.W., van Marwijk Kooy, M., Schaafsma, R., Biemond, B.J., Beeker, A., Hoogendoorn, M., van Rees, B.P., de Weerdt, O., Wegman, J., Libourel, W.J., Luykx-de Bakker, S.A., Minnema, M.C., Brouwer, R.E., Croon-de Boer, F., Eefting, M., Jie, K.S., van de Loosdrecht, A.A., Koedam, J., Veeger, N.J., Vellenga, E. & Huls, G. (2011) Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the dutch azacitidine compassionate named patient programme. British Journal of Haematology, 155, 599-606.
6. Itzykson, R., Kosmider, O., Cluzeau, T., Mansat-De Mas, V., Dreyfus, F., Beyne-Rauzy, O., Quesnel, B., Vey, N., Gelsi-Boyer, V., Raynaud, S., Preudhomme, C., Ades, L., Fenaux, P., Fontenay, M. & Groupe Francophone des Myelodysplasies (GFM) (2011a) Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia, 25, 1147-1152.
7. Itzykson, R., Thepot, S., Quesnel, B., Dreyfus, F., Beyne-Rauzy, O., Turlure, P., Vey, N., Recher, C., Dartigeas, C., Legros, L., Delaunay, J., Salanoubat, C., Visanica, S., Stamatoullas, A., Isnard, F., Marfaing-Koka, A., de Botton, S., Chelghoum, Y., Taksin, A.L., Plantier, I., Ame, S., Boehrer, S., Gardin, C., Beach, C.L., Ades, L., Fenaux, P. & Groupe Francophone des Myelodysplasies(GFM) (2011b) Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood, 117, 403-411.
8. Itzykson, R., Thepot, S., Quesnel, B., Dreyfus, F., Recher, C., Wattel, E., Gardin, C., Ades, L. & Fenaux, P. (2012) Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort. Blood, 119, 6172-6173.
9. Lamarque, M., Raynaud, S., Itzykson, R., Thepot, S., Quesnel, B., Dreyfus, F., Rauzy, O.B., Turlure, P., Vey, N., Recher, C., Dartigeas, C., Legros, L., Delaunay, J., Visanica, S., Stamatoullas, A., Fenaux, P. & Ades, L. (2012) The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience. Blood, 120, 5084-5085.
10. Mishra, A., Corrales-Yepez, M., Ali, N.A., Kharfan-Dabaja, M., Padron, E., Zhang, L., Epling-Burnette, P.K., Pinilla-Ibarz, J., Lancet, J.E., List, A.F. & Komrokji, R.S. (2013) Validation of the revised international prognostic scoring system in treated patients with myelodysplastic syndromes. American Journal of Hematology, 88, 566-570.
11. Neukirchen, J., Lauseker, M., Blum, S., Giagounidis, A., Lubbert, M., Martino, S., Siragusa, S., Schlenk, R.F., Platzbecker, U., Hofmann, W.K., Gotze, K., Palumbo, G.A., Magrin, S., Kundgen, A., Aul, C., Hildebrandt, B., Hasford, J., Kobbe, G., Haas, R. & Germing, U. (2014) Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. Leukemia Research, 38, 57-64.
12. Prebet, T., Gore, S.D., Esterni, B., Gardin, C., Itzykson, R., Thepot, S., Dreyfus, F., Rauzy, O.B., Recher, C., Ades, L., Quesnel, B., Beach, C.L., Fenaux, P. & Vey, N. (2011) Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. Journal of Clinical Oncology, 29, 3322-3327.
13. Prebet, T., Sun, Z., Figueroa, M.E., Ketterling, R., Melnick, A., Greenberg, P.L., Herman, J., Juckett, M., Smith, M.R., Malick, L., Paietta, E., Czader, M., Litzow, M., Gabrilove, J., Erba, H.P., Gore, S.D. & Tallman, M.S. (2014) Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US leukemia intergroup trial E1905. Journal of Clinical Oncology, 32, 1242-1248.
14. Savic, A., Marisavljevic, D., Kvrgic, V. & Stanisavljevic, N. (2013) Validation of the revised international prognostic scoring system for patients with myelodysplastic syndromes. Acta Haematologica, 131, 231-238.
15. Sekeres, M.A., Tiu, R.V., Komrokji, R., Lancet, J., Advani, A.S., Afable, M., Englehaupt, R., Juersivich, J., Cuthbertson, D., Paleveda, J., Tabarroki, A., Visconte, V., Makishima, H., Jerez, A., Paquette, R., List, A.F. & Maciejewski, J.P. (2012) Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood, 120, 4945-4951.
16. Silverman, L.R., Demakos, E.P., Peterson, B.L., Kornblith, A.B., Holland, J.C., Odchimar-Reissig, R., Stone, R.M., Nelson, D., Powell, B.L., DeCastro, C.M., Ellerton, J., Larson, R.A., Schiffer, C.A. & Holland, J.F. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. Journal of Clinical Oncology, 20, 2429-2440.
17. Silverman, L.R., McKenzie, D.R., Peterson, B.L., Holland, J.F., Backstrom, J.T., Beach, C.L., Larson, R.A. & Cancer and Leukemia Group B (2006) Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the cancer and leukemia group B. Journal of Clinical Oncology, 24, 3895-3903.
18. Steensma, D.P. (2012) Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?. Best Practice & Research Clinical Haematology, 25, 443-451.
19. Voso, M.T., Fenu, S., Latagliata, R., Buccisano, F., Piciocchi, A., Aloe-Spiriti, M.A., Breccia, M., Criscuolo, M., Andriani, A., Mancini, S., Niscola, P., Naso, V., Nobile, C., Piccioni, A.L., D'Andrea, M., D'Addosio, A., Leone, G. & Venditti, A. (2013) Revised international prognostic scoring system (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO prognostic scoring system: validation by the gruppo romano mielodisplasie italian regional database. Journal of Clinical Oncology, 31, 2671-2677.
20. Zeidan, A.M. & Gore, S.D. (2013) Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation? Expert Review of Hematology, 6, 539-542.
21. Zeidan, A.M. & Komrokji, R.S. (2013) There's risk, and then there's RISK: the latest clinical prognostic risk stratification models in myelodysplastic syndromes. Current Hematologic Malignancy Reports, 8, 351-360.
22. Zeidan, A.M., Linhares, Y. & Gore, S.D. (2013a) Current therapy of myelodysplastic syndromes. Blood Reviews, 27, 243-259.
23. Zeidan, A.M., Kharfan-Dabaja, M.A. & Komrokji, R.S. (2013b) Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. Current Opinion in Hematology, 21, 123-130.
24. Zeidan, A.M., Faltas, B., Douglas Smith, B. & Gore, S. (2013c) Myelodysplastic syndromes: what do hospitalists need to know? Journal of Hospital Medicine, 8, 351-357.
25. Zeidan, A.M., Smith, B.D., Komrokji, R.S. & Gore, S.D. (2013d) Prognostication in myelodysplastic syndromes: beyond the international prognostic scoring system (IPSS). The American Journal of Medicine, 126, e25.
26. Zeidan, A.M., Gore, S.D., McNally, D.L., Baer, M.R., Hendrick, F., Mahmoud, D. & Davidoff, A.J. (2013e) Lenalidomide performance in the real world: patterns of use and effectiveness in a medicare population with myelodysplastic syndromes. Cancer, 119, 3870-3878.
27. Zeidan, A.M., Gore, S.D. & Komrokji, R.S. (2013f) Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go? Expert Review of Hematology, 6, 251-254.
28. Zeidan, A.M., Prebet, T., Saad Aldin, E. & Gore, S.D. (2014a) Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling? Expert Review of Hematology, 7, 191-194.
29. Zeidan, A.M., Lee, J.W., Prebet, T., Greenberg, P., Sun, Z., Juckett, M., Smith, M.R., Paietta, E., Gabrilove, J., Erba, H.P., Tallman, M.S., Gore, S.D. & the Eastern Cooperative Oncology Group (ECOG) and North American Leukemia intergroup (2014b) Comparison of the prognostic utility of the revised international prognostic scoring system and the French prognostic scoring system in azacitidine-treated patients with myelodysplastic syndromes. British Journal of Haematology, doi: 10.1111/bjh.12884.